GLI1 and acute myeloid leukemia: Disruption of the Smo/Gli-1 pathway has been demonstrated to improve chemotherapeutic effects in AML, and Smo inhibitors have been approved by the Food and Drug Administration (FDA) to treat AML patients in combination with chemotherapy [37–39].